Lasvic Intravenous (lascufloxacin IV) / Kyorin - LARVOL DELTA

Severe Influenza Patients Who Received Ventilator Management During the 2024 to 2025 Major Influenza-Endemic Season in a Tertiary Hospital in Japan. (PubMed, Int Med Case Rep J) - "Intravenous peramivir and piperacillin/tazobactam were administered for 2 days followed by lascufloxacin and linezolid for 2 weeks...He showed severe hypoxia and massive ground-glass opacities (GGOs) in both lung fields, but he recovered after administration of peramivir and levofloxacin with prednisolone for 2 days and 2 weeks, respectively, with non-invasive positive pressure support...All three patients had not received influenza vaccines and were not elderly. Although the emphasis on most vaccines has decreased after the COVID-19 pandemic appears to have subsided, we should stress the importance of influenza vaccines and improvement of critical care protocols, because severe influenza can be a concern for young and middle-aged adults during the influenza season after the post COVID-19 pandemic period."

Journal • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Critical care • Genetic Disorders • Heart Failure • Hematological Malignancies • Infectious Disease • Inflammation • Influenza • Multiple Myeloma • Nephrology • Novel Coronavirus Disease • Obesity • Oncology • Pneumonia • Renal Disease • Respiratory Diseases

Efficacy and Safety of Intravenous-to-Oral Lascufloxacin Switch Therapy in Community-Onset Pneumonia: A Single-Arm, Open-Label Clinical Trial. (PubMed, Cureus) - "Switch therapy using LSFX presented high efficacy and acceptable safety profiles against mild-to-moderate severity of COP. This strategy of using the same drug in both intravenous and oral formulations is quite innovative. LSFX may potentially emerge as one of the preferred options for treating COP."

Clinical • Journal • Hepatology • Infectious Disease • Liver Failure • Pneumonia • Respiratory Diseases

Clinical Effectiveness of Lascufloxacin Drip Infusion, A Novel Fluoroquinolone Antibiotic, for the Treatment of Patients With Elderly Pneumonia and Lung Abscess (ATS 2024) - "These data suggested that intravenous administration of LSFX was effective for bacterial pneumonia, including lung abscess, and it appears to have broad antimicrobial activity and good tissue penetration into the lung."

Clinical • Late-breaking abstract • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Effectiveness of Drip Infusion of Lascufloxacin, a Novel Fluoroquinolone Antibiotic, for Patients with Pneumonia Including Chronic Lung Disease Exacerbations and Lung Abscesses. (PubMed, Infect Drug Resist) - "There were no severe adverse effects in any of the 55 patients. Based on these data, intravenous administration of LSFX seems effective for bacterial pneumonia, including chronic lung disease exacerbations and lung abscesses, and it appears to have broad antimicrobial activity and good tissue penetration into the lung."

Journal • Infectious Disease • Pneumococcal Infections • Pneumonia • Pulmonary Disease • Respiratory Diseases

Evaluation of efficacy and safety of lascufloxacin for nursing and healthcare associated pneumonia: single-arm, open-label clinical trial: A study protocol. (PubMed, Medicine (Baltimore)) - "NHCAP is a common pneumonia in clinical settings and a notable pneumonia whose mortality is high compared to community-acquired pneumonia. The present study showed the efficacy and safety of LSFX against NHCAP, which could lead to a larger number of therapeutic options for NHCAP."

Journal • Infectious Disease • Pneumonia • Respiratory Diseases